Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

Abstract

Alemtuzumab-associated ITP occurs in approximately 2% of patients and is responsive to therapy. Careful monitoring is key for detection and favorable outcomes.